US/UK/Canada

Share

Links

Quotes

In the past, resistance mechanisms were usually thought of as static. Our study demonstrates, conversely, that a binary designation of resistance may oversimplify cancer’s true biology. These genetic mutations can fluctuate over time, and some patients can harbor more than one mutation.
Zofia Piotrowska, MD, lead author of the study
In an era where cancer treatment is increasingly personalized to the biology of each individual patient, our findings highlight the importance of molecular testing and the need for improved, noninvasive methods for serial testing.
Zofia Piotrowska, MD
In the past year, the Vice President’s moonshot initiative has brought critical attention to the need for greater collaboration and innovation in cancer research, and we are invigorated at the prospect of radiation oncology being an instrumental component of future progress. Moving forward, we must maintain the focus on advancing both the science and practice of cancer care while aligning our efforts to move Congress to authorize the $700 million requested by the President for cancer research initiatives. Substantial, predictable financial support is essential to sustain the fight to eradicate cancer.
Bruce G. Haffty, MD, FASTRO, past Chair of ASTRO’s Board of Directors
The goal of ASTRO’s 2016 Annual Meeting is to highlight the latest scientific and technological advances while emphasizing the importance of radiation oncology in providing value to cancer patients through cure and palliation.
ASTRO President David C. Beyer, MD, FASTRO
Pick a time period -
Tags ( Active)

Data indicates that HPV-positive oropharyngeal cancer patients are nearly twice as likely to survive as HPV-negative patients

Scottsdale, Ariz., February 20, 2014—A retrospective analysis of oropharyngeal patients with recurrence of disease after primary therapy in the Radiation Therapy Oncology Group (RTOG) studies 0129 or 0522 found that HPV-positive patients had a higher overall survival (OS) rate than HPV-negative patients (at two years post-treatment, 54.6 percent vs. 27.6 percent, respectively), according to research presented today at the 2014 Multidisciplinary Head and Neck Cancer Symposium. The analysis included 181 patients with stage III-IV oropharyngeal squamous cell carcinoma (OPSCC) with known HPV

Patients with oropharyngeal cancer report quality of voice and speech affected post-treatment

Study indicates limiting radiation dose to the glottic larynx beneficialScottsdale, Ariz., February 20, 2014—Oropharyngeal cancer patients treated with combined chemotherapy and radiation therapy reported a decrease in their voice and speech quality (VSQ) for up to one year after the completion of treatment, according to research presented today at the 2014 Multidisciplinary Head and Neck Cancer Symposium. The study further shows that limiting the dose of radiation to the glottic larynx (GL) to less than 20 Gy resulted in a decrease in post-treatment VSQ problems, and that patient-reported

Oropharyngeal cancer patients report benefit in salivary function with reduction of radiation dose to bilateral IB lymph nodes

Scottsdale, Ariz., February 20, 2014—For head and neck cancer patients undergoing radiation therapy, a reduction in the amount of radiation treatment volume to the submandibular (level IB) lymph nodes resulted in better patient-reported salivary function, according to research presented today at the 2014 Multidisciplinary Head and Neck Cancer Symposium. The study results also found significant reductions in radiation dose to the salivary organs, and good local regional control. Researchers evaluated 125 patients with node-positive oropharyngeal cancer who received chemoradiation at

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Media